Evidence map›Paper›PMID 38180574›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

Production of the PET radionuclide

Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka, Martin Kreller

Open access · goldAbstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. AreJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  2. Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Pharmaceutics · 2025
    Article
  5. Article
  6. Scalability study on [EJNMMI radiopharmacy and chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Santiago Andrés BrühlmannInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328, Dresden, Germany.
Martin WaltherInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328, Dresden, Germany. m.walther@hzdr.de.ORCID http://orcid.org/0000-0002-0474-8492
Klaus KopkaInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328, Dresden, Germany.
Martin KrellerInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328, Dresden, Germany.
Helmholtz-Zentrum Dresden-Rossendorf · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are only a handful of true theranostic matched pairs, and in particular the theranostic radiocopper trio

resultsProton irradiation of enriched

conclusionsIn the current article a comprehensive novel production method for the PET radionuclide

Indexed as

Copper-61CopperNosticsPETRadiocopperTarget chemistryTargetryTheranostics

Identifiers

PMID38180574
PMCPMC10770005
OpenAlexW4390617060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.